Association of GLP1RAs with risk of chronic obstructive pulmonary disease: evidence from drug target Mendelian randomization
Abstract Background Glucose-lowering glucagon-like peptide-1 receptor agonists (GLP1RAs) are widely used to treat type 2 diabetes (T2D) and obesity. However, their potential benefits in pulmonary diseases remain unclear. To address this, we used Mendelian randomization (MR) analysis to assess the ca...
Saved in:
| Main Authors: | Sijia Lai, Yaohui Feng, Lu Li, Jiayu Zhao, Zhenyu Wang, Yanli Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13098-025-01866-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic potential of GLP-1RAs in sleep apnea with genetic associations to type 2 diabetes
by: Fang Cheng, et al.
Published: (2025-04-01) -
Assessing GLP-1 RAs in Diabetic Gastroparesis: A Literature Review
by: Jacob Itkin, et al.
Published: (2025-06-01) -
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
by: Xu He, et al.
Published: (2025-01-01) -
Genetic analysis of the correlation between GLP1 action and metabolic liver disease: Insights from Mendelian randomization analysis
by: Zhiqiang Ma, et al.
Published: (2025-08-01) -
Assessing the Causal Relationship between Chronic Obstructive Pulmonary Disease and Tuberculosis: A Mendelian Randomization Study
by: Wang Z, et al.
Published: (2025-05-01)